The Treatment of Enterobiasis with new Formulations of Dithiazanine Iodide

View More View Less


Various new formulations of tablets of dithiasanine iodide were administered to 81 teen-age individuals infected with Enterobius vermicularis. As compared with commercial tablets, administered to 43 patients, the new formulations gave evidence of improved patient tolerance without loss of therapeutic efficacy.

Commercial tablets at a dosage level of 300 mg daily for 5 days apparently cured all 16 subjects treated. Thirteen subjects complained of side effects, among whom 7 vomited once and 3 vomited twice or more. In a similar group receiving half the dose, the incidence of side effects was significantly reduced; but there were 4 treatment failures.

The incidence of side effects in the group receiving the four tablet-modifications was significantly reduced as compared with that in the group receiving the commercial tablets in full dosage or half dosage. There were two treatment failures. Best tolerance was noted in 23 patients receiving the tablets containing a methylcellulose core. Four had some side effects, among whom only one vomited once and none vomited twice.

Author Notes

Lilly Laboratory for Clinical Research, Marion County General Hospital, Indianapolis.

The Lilly Research Laboratories, Indianapolis.